AbbVie Says Qulipta Outperformed Topiramate in Phase 3 Trial
AbbVie reported that Qulipta outperformed topiramate in a Phase 3 migraine prevention trial.
Related stories
Saia 3Q LTL Tonnage Per Workday Rose 8.9%
M impact | EQUITY | Oct 29, 2026, 11:54 AM UTC
Bahrain National Hotels Reports Q3 Attributable Net Profit of 301,580 Dinars
M impact | EQUITY | Oct 29, 2026, 11:53 AM UTC
Jordan Investment and Multiple Transport reports Q3 revenue of 563,945 dinars
M impact | EQUITY | Oct 29, 2026, 11:53 AM UTC
Jordan Investment and Multiple Transport Reports Q3 Loss of 648,741 Dinars
M impact | EQUITY | Oct 29, 2026, 11:53 AM UTC
Victory Giant Tech Plans Up to $800M Thailand and $700M Vietnam Investments
Victory Giant Tech says it plans to invest up to $800 million in its Thailand unit and $700 million in its Vietnam unit via a Singapore subsidiary.
M impact | EQUITY | Oct 29, 2026, 11:53 AM UTC
Kalshi Raises Capital at a Reported Valuation
Kalshi raised capital as it expands beyond prediction markets.
M impact | EQUITY | Oct 29, 2026, 11:52 AM UTC